Evidence map›Paper›PMID 31413526›Full record

ReviewWorld journal of gastroenterology2019

Consensus on management of hepatitis C virus infection in resource-limited Ukraine and Commonwealth of Independent States regions.

Massimo Giuseppe Colombo, Erkin Isakovich Musabaev, Umed Yusupovich Ismailov, Igor A Zaytsev, Alexander V Nersesov, Igor Anatoliyevich Anastasiy, Igor Alexandrovich Karpov, Olga A Golubovska, Kulpash S Kaliaskarova, Ravishankar Ac and 1 more

Abstract readReviewConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Massimo Giuseppe ColomboResearch and Clinical Center, Department of Medicine, Humanitas Hospital, Rozzano 20089, MI, Italy. massimo.colombo@humanitas.it.
Erkin Isakovich MusabaevResearch Institute of Virology, Scientific Research Institute of Virology, Tashkent 100194, Uzbekistan.
Umed Yusupovich IsmailovHepatoсenter, Research Institute of Virology, Scientific Research Institute of Virology, Tashkent 100194, Uzbekistan.
Igor A ZaytsevDepartment of Therapy, Infectious Diseases and Dermatology, Bogomolets National Medical University, Kyiv 01601, Ukraine.
Alexander V NersesovDepartment of Gastroenterology and Hepatology, National Research Institute of Cardiology and Internal Diseases, Almaty 050000, Kazakhstan.
Igor Anatoliyevich AnastasiyDepartment Infectious Diseases, Bogomolets National Medical University, Kyiv 01601, Ukraine.
Igor Alexandrovich KarpovDepartment Infectious Diseases, Belarus State Medical University, Minsk 220116, Belarus.
Olga A GolubovskaDepartment Infectious Diseases, Bogomolets National Medical University, Kyiv 01601, Ukraine.
Kulpash S KaliaskarovaHepatology, Ministry of Health, Astana 010000, Kazakhstan.
Ravishankar AcMedical Affairs, Mylan Pharmaceuticals Private Limited, Kadubeesanahalli, Bengaluru 560103, India.
Sanjay HadigalMedical Affairs, Mylan Pharmaceuticals Private Limited, Kadubeesanahalli, Bengaluru 560103, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Globally, 69.6 million individuals were infected with hepatitis C virus (HCV) infection in 2016. Of the six major HCV genotypes (GT), the most predominant one is GT1, worldwide. The prevalence of HCV in Central Asia, which includes most of the Commonwealth of Independent States (CIS), has been estimated to be 5.8% of the total global burden. The predominant genotype in the CIS and Ukraine regions has been reported to be GT1, followed by GT3. Inadequate HCV epidemiological data, multiple socio-economic barriers, and the lack of region-specific guidelines have impeded the optimal management of HCV infection in this region. In this regard, a panel of regional experts in the field of hepatology convened to discuss and provide recommendations on the diagnosis, treatment, and pre-, on-, and posttreatment assessment of chronic HCV infection and to ensure the optimal use of cost-effective antiviral regimens in the region. A comprehensive evaluation of the literature along with expert recommendations for the management of GT1-GT6 HCV infection with the antiviral agents available in the region has been provided in this review. This consensus document will help guide clinical decision-making during the management of HCV infection, further optimizing treatment outcomes in these regions.

Indexed as

Antiviral AgentsClinical Decision-MakingCommonwealth of Independent StatesDrug Therapy, CombinationGastroenterologyGenotypeHealth ResourcesHepacivirusHepatitis C, ChronicHumansSocioeconomic FactorsSustained Virologic ResponseUkraineAntiviral AgentsAntiviral agentsCommonwealth of Independent StatesGenotypeHepatitis C virusSustained virologic responseUkraine

Identifiers

PMID31413526
PMCPMC6689802

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.